Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01676961 · OUTCOME

Percentage of Patients Who Experienced Thrombosis or Marrow Fibrosis

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy · Source last updated 2018-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 1.5 years

Analysis population: Patient data was not analyzefd

Groups in this outcome

Supportive Care (Romiplostim)

Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen.. romiplostim: Given SC

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Supportive Care (Romiplostim)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen.. romiplostim: Given SC
    id
    OG000
    title
    Supportive Care (Romiplostim)
population Description
Patient data was not analyzefd
reporting Status
POSTED
time Frame
Up to 1.5 years
title
Percentage of Patients Who Experienced Thrombosis or Marrow Fibrosis
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice